Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03160-4
Abstract: Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response rate. Although cytokine release syndrome… read more here.
Keywords: therapy; bcma targeted; antigen receptor; car ... See more keywords
Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207919
Abstract: Background: Promising results have been seen in heavily pretreated myeloma patients (pts) after the use of novel T-cell redirected bispecifics targeting BCMA, GPRC5d or FcRH5 or anti-BCMA targeted immunotherapies (bispecifics, ADC or CAR T-cell products).… read more here.
Keywords: bcma; anti bcma; therapy; cell ... See more keywords
Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3916
Abstract: B-cell maturation antigen (BCMA)-targeted therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies have demonstrated therapeutic efficacy with robust response rates and improved survival in patients with relapsed/refractory multiple myeloma (RRMM). Prior… read more here.
Keywords: bcma; anti bcma; therapy; car ... See more keywords
Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.742.742
Abstract: Patients with relapsed/refractory MM (RRMM) rarely obtain durable remissions with available therapies. Clinical use of BCMA targeted CAR T cell therapy was first reported in 12/2015 for RRMM, and based on small numbers, preliminary results… read more here.
Keywords: targeted car; car cells; bcma targeted; cell ... See more keywords
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000466
Abstract: Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials. read more here.
Keywords: myeloma; serial treatment; targeted therapy; bcma ... See more keywords